Comparing IceCure Medical (NASDAQ:ICCM) & West Pharmaceutical Services (NYSE:WST)
by Doug Wharley · The Cerbat GemWest Pharmaceutical Services (NYSE:WST – Get Free Report) and IceCure Medical (NASDAQ:ICCM – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, analyst recommendations, profitability, institutional ownership and earnings.
Earnings & Valuation
This table compares West Pharmaceutical Services and IceCure Medical”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| West Pharmaceutical Services | $3.07 billion | 8.49 | $493.70 million | $7.81 | 47.45 |
| IceCure Medical | $3.38 million | 1.76 | -$15.06 million | ($8.52) | -0.20 |
West Pharmaceutical Services has higher revenue and earnings than IceCure Medical. IceCure Medical is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
West Pharmaceutical Services has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Comparatively, IceCure Medical has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500.
Profitability
This table compares West Pharmaceutical Services and IceCure Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| West Pharmaceutical Services | 16.98% | 20.11% | 14.83% |
| IceCure Medical | -427.67% | -174.26% | -112.58% |
Analyst Ratings
This is a breakdown of current recommendations and price targets for West Pharmaceutical Services and IceCure Medical, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| West Pharmaceutical Services | 0 | 2 | 12 | 0 | 2.86 |
| IceCure Medical | 2 | 0 | 3 | 0 | 2.20 |
West Pharmaceutical Services presently has a consensus target price of $382.00, indicating a potential upside of 3.07%. IceCure Medical has a consensus target price of $52.50, indicating a potential upside of 2,934.68%. Given IceCure Medical’s higher possible upside, analysts plainly believe IceCure Medical is more favorable than West Pharmaceutical Services.
Institutional & Insider Ownership
93.9% of West Pharmaceutical Services shares are held by institutional investors. Comparatively, 0.6% of IceCure Medical shares are held by institutional investors. 0.6% of West Pharmaceutical Services shares are held by company insiders. Comparatively, 2.4% of IceCure Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
West Pharmaceutical Services beats IceCure Medical on 12 of the 14 factors compared between the two stocks.
About West Pharmaceutical Services
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. This segment also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. The company serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
About IceCure Medical
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.